Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

FOSAPREPITANT DIMEGLUMINE for Breast cancer: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 6 adverse event reports in the FDA FAERS database where FOSAPREPITANT DIMEGLUMINE was used for Breast cancer.

Most Reported Side Effects for FOSAPREPITANT DIMEGLUMINE

Side Effect Reports % Deaths Hosp.
Dyspnoea 142 16.0% 39 69
Pyrexia 136 15.3% 34 109
Nausea 130 14.6% 29 75
Infusion related reaction 83 9.4% 37 50
Diarrhoea 80 9.0% 27 62
Vomiting 71 8.0% 31 54
Rash 66 7.4% 33 50
Hypersensitivity 65 7.3% 37 46
Stomatitis 64 7.2% 34 51
Decreased appetite 62 7.0% 26 40
Pain 62 7.0% 33 47
Drug ineffective 60 6.8% 24 40
Insomnia 60 6.8% 38 49
Abdominal pain 59 6.6% 23 39
Neutropenia 58 6.5% 7 34

Other Indications for FOSAPREPITANT DIMEGLUMINE

Prophylaxis of nausea and vomiting (551) Product used for unknown indication (78) Nausea (23) Premedication (18) Vomiting (16) Chemotherapy (10) Antiemetic supportive care (9) Covid-19 (5) Lung adenocarcinoma metastatic (5) Rheumatoid arthritis (5)

Other Drugs Used for Breast cancer

TRASTUZUMAB (15,522) PALBOCICLIB (13,075) DOCETAXEL (11,735) PACLITAXEL (10,215) LETROZOLE (9,332) CYCLOPHOSPHAMIDE (8,826) PERTUZUMAB (7,532) RIBOCICLIB (6,953) CAPECITABINE (5,767) EPIRUBICIN (5,444)

Related Pages

FOSAPREPITANT DIMEGLUMINE Full Profile All Breast cancer Drugs FOSAPREPITANT DIMEGLUMINE Demographics FOSAPREPITANT DIMEGLUMINE Timeline